Cannabinoid Acylation for Crystalline Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and purifying cannabinoids, such as THCA and CBDA, are cumbersome and do not provide desired purities due to the oily nature of cannabinoids, which makes them difficult to crystallize, and their tendency to decarboxylate during extraction and storage.
Innovation Solution
A process involving acylation of crude plant extracts with an acylation agent, such as acetic anhydride, and a chemical base, like triethylamine, to form THCA alkanoates and CBDA di-alkanoates, which can then be isolated through crystallization, thereby overcoming the challenges of decarboxylation and oily consistency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional extraction and purification methods are used, then cannabinoids can be isolated, but the compounds decarboxylate and purity is insufficient due to oily nature
Solution Approach 1:
The invention changes the chemical parameters of the cannabinoid compounds by converting them to derivatized forms (esters, amides, carbamates) through reaction with reagents like diazomethane, methyl iodide, and other alkylating agents. This parameter change transforms the oily, difficult-to-purify cannabinoids into derivatives that can be crystallized and purified to high purity levels while preventing decarboxylation
Solution Approach 2:
The invention utilizes phase transitions by converting the oily cannabinoid compounds into crystalline derivatives. The derivatized compounds exhibit different physical properties including crystalline form, which allows for effective purification through crystallization techniques. This phase transition from oily liquid to crystalline solid enables high purity isolation while maintaining compound integrity
2Productivity
If elevated temperatures are applied during extraction, then extraction efficiency improves, but decarboxylation of CBDA and THCA occurs
Solution Approach 1:
The invention applies preliminary action by performing derivatization reactions on the extracted cannabinoids under mild conditions before any high-temperature processing occurs. The derivatized compounds are then purified through crystallization at low temperatures, preventing decarboxylation throughout the entire process while maintaining extraction efficiency through the initial mild extraction step
3Ease of operation
If prolonged storage at room temperature is used, then storage simplicity is maintained, but decarboxylation of THCA and CBDA occurs
Solution Approach 1:
The invention creates stable, crystalline derivatives that serve as long-term storage forms. These derivatized compounds can be stored at room temperature indefinitely without decarboxylation, effectively replacing the need for complex cold storage conditions. The derivatives act as stable intermediates that can be stored simplistically while maintaining integrity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the efficient synthesis and purification of THCA acetate and CBDA di-acetate in pure, crystalline form, which is more stable and easier to handle than their non-esterified counterparts, thus improving compound integrity and purity.
Implementation Method 1
contacting and/or reacting the crude plant extract or the CBDA with an acylation agent, preferably an acetylation agent, and a chemical base, to obtain THCA alkanoate and/or CBDA di-alkanoate
Implementation Method 2
isolating the obtained THCA alkanoate and/or CBDA di-alkanoate, preferably THCA acetate and/or CBDA di-acetate, wherein isolation is carried out by means of crystallization
Data Source
AI summary
The invention relates to a novel process for the synthesis and/or purification of tetrahydrocannabinolic acid (THCA) alkanoates and/or cannabidiolic acid (CBDA) di-alkanoates. The invention also provides novel derivatives of CBDA di-alkanoates and THCA alkanoates according to Formula I, wherein R1=methyl-4-(prop-1-en-2-yl)-cyclohex-1-ene-3-yl (limonenyl); wherein R2=acetate, propionate, butyrate, or OH; wherein R3=propyl, pentyl, or heptyl; wherein R4=methyl, ethyl, or propyl; wherein R5=methyl, ethyl, or propyl, or wherein R1=methyl-4-(2-propyl)cyclohex-1-ene-3-yl or methyl-4-(2-propyl)-cyclohex-5-ene-3-yl, wherein R2═O, and R1 and R2 together form a ring structure in which R2 is an internal ring atom, wherein R3=propyl, pentyl, or heptyl, wherein R4=methyl, ethyl, or propyl, and wherein R5=methyl, ethyl, or propyl, or wherein R1=methyl-4-(2-propyl)-cyclohex-1-ene-3-yl, wherein R2═O, and R1 and R2 together form a ring structure in which R2 is an internal ring atom, wherein R3=propyl, pentyl, or heptyl, wherein R4 and R5 vanish, i.e. are radicals forming a direct bond to each other.